Abstract
Aromatase inhibitors have the potential to treat a wide spectrum of diseases where estradiol is required to manifest clinical symptoms. Their use was initially indicated for the treatment of hormone-dependent advanced postmenopausal breast cancer, but little is known regarding their role in gynecology. This review will address the current use of aromatase inhibitors in the treatment of ovulation induction, endometriosis and uterine myomata.